Prestige BioPharma Limited (KRX:950210)
South Korea
· Delayed Price · Currency is KRW 10,030
+10 (0.10%)
At close: Mar 6, 2026
Prestige BioPharma Income Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | 2020 - 2019 |
| Revenue | 19,023 | 14,326 | 689.08 | 161.84 | - | - | Upgrade
|
| Revenue Growth (YoY) | 224.15% | 1978.97% | 325.77% | - | - | - | Upgrade
|
| Cost of Revenue | 23,912 | 26,563 | 11,291 | 33.94 | 228.95 | 284.85 | Upgrade
|
| Gross Profit | -4,889 | -12,237 | -10,602 | 127.9 | -228.95 | -284.85 | Upgrade
|
| Selling, General & Admin | 37,095 | 23,307 | 19,108 | 58,231 | 54,422 | 16,432 | Upgrade
|
| Research & Development | 19,123 | 19,123 | 23,414 | - | - | - | Upgrade
|
| Amortization of Goodwill & Intangibles | 2,782 | 2,782 | 178.99 | - | - | - | Upgrade
|
| Other Operating Expenses | 520.59 | 520.59 | 1,326 | - | - | - | Upgrade
|
| Operating Expenses | 68,136 | 54,348 | 51,636 | -906.28 | 122,460 | 18,099 | Upgrade
|
| Operating Income | -73,025 | -66,585 | -62,238 | 1,034 | -122,689 | -18,384 | Upgrade
|
| Interest Expense | -7,626 | -7,626 | -7,404 | -950.8 | -18.85 | -6.2 | Upgrade
|
| Interest & Investment Income | 9,137 | 9,137 | 12,402 | 10,464 | 2,729 | 158.22 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -16.96 | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 2,145 | 2,145 | -4,232 | -924.24 | -1,592 | -4,620 | Upgrade
|
| Other Non Operating Income (Expenses) | 5,384 | 7,397 | 6,693 | 4,034 | 2,282 | 414.8 | Upgrade
|
| EBT Excluding Unusual Items | -63,986 | -55,533 | -54,779 | 13,639 | -119,288 | -22,437 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 15,081 | Upgrade
|
| Gain (Loss) on Sale of Assets | -6.7 | -6.7 | 89.4 | 72.12 | 211.59 | -0.36 | Upgrade
|
| Asset Writedown | 59,462 | 59,462 | - | -15,807 | -91,573 | - | Upgrade
|
| Pretax Income | -4,530 | 3,923 | -54,689 | -2,095 | -210,649 | -7,357 | Upgrade
|
| Income Tax Expense | -318.57 | -248.48 | 408.68 | 763.28 | 800.66 | 34.08 | Upgrade
|
| Earnings From Continuing Operations | -4,212 | 4,171 | -55,098 | -2,859 | -211,450 | -7,391 | Upgrade
|
| Minority Interest in Earnings | 17,888 | 18,126 | 22,177 | 20,428 | - | - | Upgrade
|
| Net Income | 13,676 | 22,297 | -32,921 | 17,569 | -211,450 | -7,391 | Upgrade
|
| Net Income to Common | 13,676 | 22,297 | -32,921 | 17,569 | -211,450 | -7,391 | Upgrade
|
| Shares Outstanding (Basic) | 60 | 60 | 60 | 60 | 60 | 52 | Upgrade
|
| Shares Outstanding (Diluted) | 60 | 60 | 60 | 60 | 60 | 52 | Upgrade
|
| Shares Change (YoY) | 0.25% | 0.44% | -0.22% | - | 16.46% | 20.98% | Upgrade
|
| EPS (Basic) | 227.41 | 370.20 | -549.00 | 292.35 | -3518.53 | -143.23 | Upgrade
|
| EPS (Diluted) | 227.41 | 370.20 | -549.00 | 292.35 | -3796.17 | -143.23 | Upgrade
|
| Free Cash Flow | -66,680 | -92,877 | -68,091 | -108,636 | -102,336 | -16,396 | Upgrade
|
| Free Cash Flow Per Share | -1108.78 | -1542.04 | -1135.49 | -1807.71 | -1702.88 | -317.73 | Upgrade
|
| Gross Margin | -25.70% | -85.42% | - | 79.03% | - | - | Upgrade
|
| Operating Margin | -383.88% | -464.80% | -9032.13% | 639.01% | - | - | Upgrade
|
| Profit Margin | 71.89% | 155.64% | -4777.60% | 10855.90% | - | - | Upgrade
|
| Free Cash Flow Margin | -350.52% | -648.33% | -9881.47% | -67125.45% | - | - | Upgrade
|
| EBITDA | -48,458 | -44,785 | -45,971 | 12,684 | -118,822 | -16,717 | Upgrade
|
| EBITDA Margin | -254.73% | - | - | 7837.31% | - | - | Upgrade
|
| D&A For EBITDA | 24,567 | 21,801 | 16,267 | 11,650 | 3,867 | 1,667 | Upgrade
|
| EBIT | -73,025 | -66,585 | -62,238 | 1,034 | -122,689 | -18,384 | Upgrade
|
| EBIT Margin | - | - | - | 639.01% | - | - | Upgrade
|
| Advertising Expenses | - | 869.23 | 970.57 | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.